Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
EARLY_PHASE1
10 participants
INTERVENTIONAL
2023-06-27
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility of Individualized Therapy for Recurrent Glioblastoma
NCT03681028
Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma
NCT00650949
AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme
NCT00305656
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
NCT03345095
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
NCT00045110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Patients will receive one of the 5 study drugs based on their recurrent tumor mutation profile and their recurrent organoid response to these drugs:
1. Afatinib
2. Dasatinib
3. Palbociclib
4. Everolimus
5. Olaparib
Afatinib
Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
Dasatinib
Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
Palbociclib
Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
Everolimus
Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
Olaparib
Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Afatinib
Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
Dasatinib
Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
Palbociclib
Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
Everolimus
Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
Olaparib
Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adult participants, male and female, aged ≥18 who have a pathologically confirmed IDH-wild type glioblastoma, with first or second progression of the tumor, after initial treatment with radiation therapy and temozolomide.
3. Recurrence is amenable to resection.
4. Performance status: ECOG ≤2.
5. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.
6. Patients of childbearing potential must adhere to the contraception requirement from screening throughout the study period up to 180 days after the last dose of study intervention. Women/men of childbearing potential must have agreed to use two highly effective contraceptive methods. In addition to routine contraceptive methods such as condom use, oral contraceptive, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.
Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
7. Able to undergo brain MRIs.
8. Females must not be breastfeeding, throughout the study period up to 180 days after the last dose of study intervention.
9. Male patients should agree to not donate sperm during the study for at least 6 months until discontinuation of study drug.
Exclusion Criteria
2. Pregnant, breast-feeding, unwilling/unable to comply with contraception requirements.
3. Patients unable to consent.
4. Abnormal (grade ≥2 CTCAE, version 5.0) laboratory values for hematology, renal, and liver function including:
1. Hemoglobin \<10,
2. Neutrophils \<1.5,
3. Platelets \<75,
4. ALT/AST \>3x ULN,
5. Bilirubin \>1.5 x ULN,
6. eGFR \<60
5. Patients with significant or recent gastrointestinal disorders with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption or severe diarrhea of any etiology) must be excluded from the clinical trial (Afatanib is not recommended in this patient population).
6. Patients with a history of ILD (interstitial lung disease) must be excluded.
7. Patients with severe hepatic impairment (Child Pugh C).
8. A significantly abnormal ECG (baseline QTcF interval \> 450 msec).
9. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
10. Patients with known pre-existing pleural effusion.
11. Active hepatitis B or C infection and/or known history of HIV infection.
12. Has known psychiatric or substance abuse disorders that would interfere with compliance with the requirements of the trial.
13. Subject will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge.
14. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks from the date of signing the informed consent form.
15. Patients who are hypersensitive to any ingredients in the formulation of the study drugs or their excipients.
16. Patients receiving active treatment for a different cancer.
17. If recent bacterial infection, patients need to have completed antibiotic course prior to commencing study drug.
18. If recent COVID-19 infection, patients must have recovered from it prior to commencing study drug.
19. Patients on strong CYP3A/p-gp inducers (for example, carbamazepine and phenytoin).
N.B. Only patients receiving SOC neurosurgery in Alberta, Canada are eligible to participate in this trial.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tom Baker Cancer Centre
OTHER
AHS Cancer Control Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paula de Robles
Role: PRINCIPAL_INVESTIGATOR
Arthur J.E. Child Comprehensive Cancer Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arthur J.E. Child Comprehensive Cancer Centre
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GBM-2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.